The 2014-2016 Ebola outbreak in West Africa was the largest in history, with nearly 28,700 cases and more than 11,300 deaths. As local and international healthcare workers responded to the outbreak, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Ministry of Health in Liberia—one of the hardest-hit countries—established PREVAIL, or the Partnership for.
As a recent example, a paper published in Nature Scientific Reports by a team of NIH-supported researchers and colleagues shows early success in rapid Ebola detection with an automated lab on a chip (2). The hybrid system, which combines microfluidics for sample preparation with optofluidics for viral detection, identifies Ebola at concentrations that are typically seen in the bloodstream of.
The NIAID team and Dartmouth College colleagues also performed a structural analysis, described in the second paper, of how mAb110 and mAb114 prevent the Ebola virus from entering target cells. Most notably, they found that mAb114 binds to a novel site of vulnerability on the Ebola virus that was previously thought to be unreachable by antibodies. “The antibody mAb114 is the first to.
Scientists from NIAID’s Vaccine Research Center and colleagues aimed to identify human antibodies against Ebola virus that could be used in a simplified treatment approach. The researchers identified and isolated anti-Ebola antibodies from the blood of a survivor of the 1995 Ebola outbreak in Kikwit, Democratic Republic of the Congo. In the laboratory, two of the antibodies, named mAb100 and.
The National Institutes of Health (NIH) has created a website, NIH Clinical Research Trials and You, to help people learn about clinical trials, why they matter, and how to participate. The site includes questions and answers about clinical trials, guidance on how to find clinical trials through ClinicalTrials.gov and other resources, and stories about the personal experiences of clinical.
The NIH has played a leading role in research on potentially lifesaving Ebola vaccines and providing crucial scientific knowledge on the virus's genetic makeup and transmission. The NIH Clinical Center's Special Clinical Studies Unit (SCSU), a 4,000 square foot, four room and seven bed isolation clinic opened in 2010 that has played an important role in that research.
A new online database allows researchers to view data on over 100,000 human genetic samples with information on Type 2 diabetes, obtained from clinical consortia supported by the NIH and the Foundation for the NIH. By facilitating access to the data, NIH's Accelerating Medicines Partnership hopes to speed research and development of new treatments.
The IF-Ebola European action, one of the five EC funded projects, stands for “Innovative technologies to Fight Ebola” intends to strategically test a novel anti-Ebola compound in early-infected patients (EBOV contacts) as a MEURI, which stands for “Monitored Emergency use of Unregistered and Experimental clinical Intervention” in Sierra Leone and Guinea.
There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed. For past and current Ebola epidemics, treatment has been primarily supportive in nature. As of August 2019, two experimental treatments known as REGN-EB3 and mAb-114 were found to be 90% effective.
The NIH is committed to preserving the public’s trust that the research we supports is conducted without bias and with the highest scientific and ethical standards. The regulation on promoting objectivity in research establishes the standards to provide a reasonable expectation that the design, conduct, and reporting of NIH research will be free from bias resulting from investigators.
Information and resources from the National Center for Complementary and Integrative Health, U.S. National Institutes of Health (NIH). The mission of NCCIH is to define, through rigorous scientific investigation, the usefulness and safety of complementary and integrative health interventions and their roles in improving health and health care.
To address these requirements and the global need for an effective therapy against Ebola virus disease, the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID) and US National Institutes of Health (NIH) developed the fully human monoclonal antibody mAb114. mAb114 was identified from a survivor of the 1995 EBOV outbreak in Kikwit, Democratic.
NIH research funding trends are particularly important since this body funds more than 300,000 research scientists and have supported 149 Nobel Laureates since 1939. Federal support of NIH has enabled the development of vaccines for Hepatitis A and Ebola, raised the prostate cancer five-year survival rate to 99%, and resulted in promising advances in the fight against antibiotic resistance.
The Genetic and Rare Diseases Information Center (GARD) is a program of the National Center for Advancing Translational Sciences (NCATS) and is funded by two parts of the National Institutes of Health (NIH): NCATS and the National Human Genome Research Institute (NHGRI). GARD provides the public with access to current, reliable, and easy-to-understand information about rare or genetic diseases.
The Clinical Center was recently announced as the first federal medical facility to be recognized by a leading health care organization for eliminating the use of paper charts and maintaining a superior electronic medical record system for inpatient care. Health Information and Management Systems Society (HIMSS) Analytics awarded the research hospital Stage 7 certification, the highest level.
News release by Scripps Research on the latest research paper on HCV vaccine co-sponsored by NIH and Ufovax. April 15, 2020. The new approach to vaccine design may also prove useful in developing a potential vaccine against the SARS-CoV-2 virus, which causes COVID-19. LA JOLLA, CA—A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a.
For all Ebola-related research, per Additional Resource (G), the Ebola Research Commission in Guinea (ERCG) must approve these protocols prior to obtaining CNERS approval. (See Ethics Committee topic, Ethics Committee and Scope of Review subtopics, and Clinical Trial Lifecycle topic, Submission Content subtopic for additional details on the EC review process and for more information on ERCG.
Global research database. WHO is gathering the latest international multilingual scientific findings and knowledge on COVID-19. The global literature cited in the WHO COVID-19 database is updated daily (Monday through Friday) from searches of bibliographic databases, hand searching, and the addition of other expert-referred scientific articles.